S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$1.18
+1.7%
$2.09
$0.39
$18.00
$5.59M3.526,071 shs6,887 shs
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
$1.47
$8.06
$2.57
$10.42
$6.42M0.645,609 shsN/A
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
PAVmed Inc. stock logo
PAVM
PAVmed
$1.95
-1.0%
$2.19
$1.60
$9.36
$17.88M0.8567,452 shs32,067 shs
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
$0.02
$0.02
$0.00
$0.03
$27.26M0.99327,275 shs100 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
+3.80%-27.04%-44.76%-77.90%-66.86%
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
0.00%-1.34%-9.26%+48.79%+17.60%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%
PAVmed Inc. stock logo
PAVM
PAVmed
+5.35%-4.83%-3.90%-32.76%-75.22%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
+20.50%+26.18%+20.50%+2.12%+13.68%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
1.6415 of 5 stars
3.00.00.04.33.00.80.0
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/A
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
N/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
2.00
Hold$21.00976.92% Upside
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K69.92N/AN/A($2.43) per share-0.49
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
$40.21M0.16$0.63 per share2.32($14.16) per share-0.10
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20
PAVmed Inc. stock logo
PAVM
PAVmed
$2.45M7.30N/AN/A($3.35) per share-0.58
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
$20.40M1.34N/AN/A($0.04) per share-0.60

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
$800K-$0.39N/AN/A1.99%-1.79%7.53%5/10/2024 (Estimated)
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A
PAVmed Inc. stock logo
PAVM
PAVmed
-$64.18M-$9.33N/AN/A-2,617.25%N/A-85.99%5/21/2024 (Estimated)
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
-$25.81M-$0.03N/AN/A-126.52%N/A-32.63%5/10/2024 (Estimated)

Latest IDXG, SNWV, PAVM, ARTH, and NVCN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
PAVmed Inc. stock logo
PAVM
PAVmed
N/A-$1.57-$1.57-$1.16N/A$1.05 million
3/21/2024Q4 2023
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/A$0.03+$0.03$0.03N/A$6.99 million
2/20/2024Q1 2024
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A-$0.57-$0.57-$0.57N/A$0.05 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.16
0.04
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
N/A
0.59
0.59
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.45
0.45
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/A
0.15
0.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
5.73%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
42.53%

Insider Ownership

CompanyInsider Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
6.50%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A
PAVmed Inc. stock logo
PAVM
PAVmed
12.60%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
16.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
84.74 million4.53 millionNot Optionable
Interpace Biosciences, Inc. stock logo
IDXG
Interpace Biosciences
1524.37 million4.08 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable
PAVmed Inc. stock logo
PAVM
PAVmed
1079.17 million8.02 millionOptionable
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
311.14 billion953.51 millionNot Optionable

IDXG, SNWV, PAVM, ARTH, and NVCN Headlines

SourceHeadline
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)
globenewswire.com - April 10 at 8:30 AM
SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial OfficerSANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer
globenewswire.com - April 1 at 4:00 PM
SANUWAVE Health, Inc. (PNK:SNWV) Q4 2023 Earnings Call TranscriptSANUWAVE Health, Inc. (PNK:SNWV) Q4 2023 Earnings Call Transcript
msn.com - March 25 at 7:14 PM
SANUWAVE Announces Record Q4 and FY2023 RevenueSANUWAVE Announces Record Q4 and FY2023 Revenue
globenewswire.com - March 22 at 6:00 AM
SANUWAVE Will Host a Conference Call on March 22, 2024 at 8:30 AM (ET) to Present the Q4 and FY2023 Financial ResultsSANUWAVE Will Host a Conference Call on March 22, 2024 at 8:30 AM (ET) to Present the Q4 and FY2023 Financial Results
globenewswire.com - March 20 at 7:00 AM
SANUWAVE Health, Inc.: SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of StockholdersSANUWAVE Health, Inc.: SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of Stockholders
finanznachrichten.de - February 23 at 10:24 AM
SANUWAVE Health Stock (OTC:SNWV) Dividends: History, Yield and DatesSANUWAVE Health Stock (OTC:SNWV) Dividends: History, Yield and Dates
benzinga.com - February 23 at 10:24 AM
SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of StockholdersSANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of Stockholders
globenewswire.com - February 22 at 5:00 PM
SEP Acquisition shareholders approve Sanuwave SPAC mergerSEP Acquisition shareholders approve Sanuwave SPAC merger
msn.com - February 1 at 7:46 PM
Sanuwave Health Announces New Financial Obligation RegistrationSanuwave Health Announces New Financial Obligation Registration
msn.com - January 26 at 10:25 PM
EQS-News: SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)EQS-News: SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)
markets.businessinsider.com - January 22 at 8:28 AM
SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)
finance.yahoo.com - January 22 at 8:28 AM
Sanuwave Health sees Q4 record revenue $6.6M-$6.8M, up 20% Y/YSanuwave Health sees Q4 record revenue $6.6M-$6.8M, up 20% Y/Y
msn.com - January 10 at 12:43 PM
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023
finance.yahoo.com - January 10 at 7:42 AM
SANUWAVE Health, Inc.: SANUWAVE Announces Q3 2023 Financial ResultsSANUWAVE Health, Inc.: SANUWAVE Announces Q3 2023 Financial Results
finanznachrichten.de - November 11 at 1:34 AM
SANUWAVE Health GAAP EPS of -$0.03, revenue of $5M; initiates Q4 outlookSANUWAVE Health GAAP EPS of -$0.03, revenue of $5M; initiates Q4 outlook
msn.com - November 10 at 10:33 AM
SANUWAVE Will Host a Conference Call on November 10, 2023 at 8:00 AM (ET) to Present the Q3 2023 Financial ResultsSANUWAVE Will Host a Conference Call on November 10, 2023 at 8:00 AM (ET) to Present the Q3 2023 Financial Results
finance.yahoo.com - November 8 at 8:20 PM
SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023
finance.yahoo.com - October 10 at 9:30 AM
Sanuwave to go public in $127.5M SPAC mergerSanuwave to go public in $127.5M SPAC merger
massdevice.com - August 24 at 5:32 PM
Sanuwave Health eyes Nasdaq listing, announces merger with SEP AcquisitionSanuwave Health eyes Nasdaq listing, announces merger with SEP Acquisition
msn.com - August 23 at 5:25 PM
SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed CompanySANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed Company
finance.yahoo.com - August 23 at 5:25 PM
SANUWAVE Health, Inc.: SANUWAVE Announces Q2 2023 Financial ResultsSANUWAVE Health, Inc.: SANUWAVE Announces Q2 2023 Financial Results
finanznachrichten.de - August 11 at 8:09 AM
SANUWAVE Announces Q2 2023 Financial ResultsSANUWAVE Announces Q2 2023 Financial Results
finance.yahoo.com - August 11 at 8:09 AM
SANUWAVE Will Host a Live Conference Call on August 11, 2023 at 8:30 AM (EDT) to Present Its Q2 2023 Financial ResultsSANUWAVE Will Host a Live Conference Call on August 11, 2023 at 8:30 AM (EDT) to Present Its Q2 2023 Financial Results
finance.yahoo.com - August 9 at 8:35 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arch Therapeutics logo

Arch Therapeutics

OTCMKTS:ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Interpace Biosciences logo

Interpace Biosciences

NASDAQ:IDXG
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
PAVmed logo

PAVmed

NASDAQ:PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
SANUWAVE Health logo

SANUWAVE Health

OTCMKTS:SNWV
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide therapeutic treatment of musculoskeletal conditions. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.